Effects of Aspirin on Intra-Platelet Vascular Endothelial Growth Factor, Angiopoietin-1, and P-Selectin Levels in Hypertensive Patients

Sunil Nadar, Andrew D. Blann, Gregory Y H Lip

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Although aspirin is useful in reducing platelet activation and cardiovascular events, its effects on platelet levels of angiogenic factors, such as vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1), and markers of platelet activation in hypertension are unknown. The aim of this study was to study the effects of aspirin on the platelet morphology, plasma and platelet levels of VEGF (sVEGF and pVEGF respectively), Ang-1 (sAng-1 and pAng-1 respectively), and P-selectin (sPsel and pPsel respectively) in patients with well controlled hypertension. Methods: A total of 35 aspirin-naive, hypertensive patients (29 male and six female; mean age 64 years) were compared with 30 (23 male, seven female, mean age 59 years) normotensive control subjects. Blood was collected for plasma VEGF, P-selectin, and Ang-1 (enzyme-linked immunoassay), intra-platelet levels of VEGF, Ang-1, and P-selectin, and platelet volume and mass. Research indices in hypertensive patients were studied before and after 3 months treatment with aspirin 75 mg daily. Results: Hypertensive patients had significantly higher plasma levels of VEGF (P = .04), Ang-1 (P < .001), as well as pVEGF (P = .008), pAng-1(P = .001), sPsel (P = .02), pPsel (P < .001), and mean platelet mass (P = .01) when compared with control subjects. After treatment with aspirin for 3 months, there were significant reductions in plasma VEGF (P = .01), pAng-1 (P = .04), sPsel (P = .001), and pPsel (P < .001) levels, but not levels of platelet VEGF and plasma Ang-1. Neither pVEGF nor pAng-1 correlated with blood pressure or with their respective plasma levels. Conclusions: The use of aspirin in high-risk hypertensive patients leads to a reduction in intra-platelet angiogenic growth factors and platelet activation. This may have implications for the use of aspirin in conditions (such as vascular disease) that have been associated with an increase in angiogenesis and platelet activation.

Original languageEnglish
Pages (from-to)970-977
Number of pages8
JournalAmerican Journal of Hypertension
Volume19
Issue number9
DOIs
Publication statusPublished - Sep 2006

Fingerprint

Angiopoietin-1
P-Selectin
Vascular Endothelial Growth Factor A
Aspirin
Blood Platelets
Platelet Activation
Angiogenesis Inducing Agents
Hypertension
Immunoenzyme Techniques
Vascular Diseases
Intercellular Signaling Peptides and Proteins
Blood Pressure

Keywords

  • angiopoeitin-1
  • aspirin
  • Hypertension
  • P-selectin
  • platelets
  • vascular endothelial growth factor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effects of Aspirin on Intra-Platelet Vascular Endothelial Growth Factor, Angiopoietin-1, and P-Selectin Levels in Hypertensive Patients. / Nadar, Sunil; Blann, Andrew D.; Lip, Gregory Y H.

In: American Journal of Hypertension, Vol. 19, No. 9, 09.2006, p. 970-977.

Research output: Contribution to journalArticle

@article{9e1f934844aa4e5f8b53029a750a3c48,
title = "Effects of Aspirin on Intra-Platelet Vascular Endothelial Growth Factor, Angiopoietin-1, and P-Selectin Levels in Hypertensive Patients",
abstract = "Background: Although aspirin is useful in reducing platelet activation and cardiovascular events, its effects on platelet levels of angiogenic factors, such as vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1), and markers of platelet activation in hypertension are unknown. The aim of this study was to study the effects of aspirin on the platelet morphology, plasma and platelet levels of VEGF (sVEGF and pVEGF respectively), Ang-1 (sAng-1 and pAng-1 respectively), and P-selectin (sPsel and pPsel respectively) in patients with well controlled hypertension. Methods: A total of 35 aspirin-naive, hypertensive patients (29 male and six female; mean age 64 years) were compared with 30 (23 male, seven female, mean age 59 years) normotensive control subjects. Blood was collected for plasma VEGF, P-selectin, and Ang-1 (enzyme-linked immunoassay), intra-platelet levels of VEGF, Ang-1, and P-selectin, and platelet volume and mass. Research indices in hypertensive patients were studied before and after 3 months treatment with aspirin 75 mg daily. Results: Hypertensive patients had significantly higher plasma levels of VEGF (P = .04), Ang-1 (P < .001), as well as pVEGF (P = .008), pAng-1(P = .001), sPsel (P = .02), pPsel (P < .001), and mean platelet mass (P = .01) when compared with control subjects. After treatment with aspirin for 3 months, there were significant reductions in plasma VEGF (P = .01), pAng-1 (P = .04), sPsel (P = .001), and pPsel (P < .001) levels, but not levels of platelet VEGF and plasma Ang-1. Neither pVEGF nor pAng-1 correlated with blood pressure or with their respective plasma levels. Conclusions: The use of aspirin in high-risk hypertensive patients leads to a reduction in intra-platelet angiogenic growth factors and platelet activation. This may have implications for the use of aspirin in conditions (such as vascular disease) that have been associated with an increase in angiogenesis and platelet activation.",
keywords = "angiopoeitin-1, aspirin, Hypertension, P-selectin, platelets, vascular endothelial growth factor",
author = "Sunil Nadar and Blann, {Andrew D.} and Lip, {Gregory Y H}",
year = "2006",
month = "9",
doi = "10.1016/j.amjhyper.2006.03.001",
language = "English",
volume = "19",
pages = "970--977",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Effects of Aspirin on Intra-Platelet Vascular Endothelial Growth Factor, Angiopoietin-1, and P-Selectin Levels in Hypertensive Patients

AU - Nadar, Sunil

AU - Blann, Andrew D.

AU - Lip, Gregory Y H

PY - 2006/9

Y1 - 2006/9

N2 - Background: Although aspirin is useful in reducing platelet activation and cardiovascular events, its effects on platelet levels of angiogenic factors, such as vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1), and markers of platelet activation in hypertension are unknown. The aim of this study was to study the effects of aspirin on the platelet morphology, plasma and platelet levels of VEGF (sVEGF and pVEGF respectively), Ang-1 (sAng-1 and pAng-1 respectively), and P-selectin (sPsel and pPsel respectively) in patients with well controlled hypertension. Methods: A total of 35 aspirin-naive, hypertensive patients (29 male and six female; mean age 64 years) were compared with 30 (23 male, seven female, mean age 59 years) normotensive control subjects. Blood was collected for plasma VEGF, P-selectin, and Ang-1 (enzyme-linked immunoassay), intra-platelet levels of VEGF, Ang-1, and P-selectin, and platelet volume and mass. Research indices in hypertensive patients were studied before and after 3 months treatment with aspirin 75 mg daily. Results: Hypertensive patients had significantly higher plasma levels of VEGF (P = .04), Ang-1 (P < .001), as well as pVEGF (P = .008), pAng-1(P = .001), sPsel (P = .02), pPsel (P < .001), and mean platelet mass (P = .01) when compared with control subjects. After treatment with aspirin for 3 months, there were significant reductions in plasma VEGF (P = .01), pAng-1 (P = .04), sPsel (P = .001), and pPsel (P < .001) levels, but not levels of platelet VEGF and plasma Ang-1. Neither pVEGF nor pAng-1 correlated with blood pressure or with their respective plasma levels. Conclusions: The use of aspirin in high-risk hypertensive patients leads to a reduction in intra-platelet angiogenic growth factors and platelet activation. This may have implications for the use of aspirin in conditions (such as vascular disease) that have been associated with an increase in angiogenesis and platelet activation.

AB - Background: Although aspirin is useful in reducing platelet activation and cardiovascular events, its effects on platelet levels of angiogenic factors, such as vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1), and markers of platelet activation in hypertension are unknown. The aim of this study was to study the effects of aspirin on the platelet morphology, plasma and platelet levels of VEGF (sVEGF and pVEGF respectively), Ang-1 (sAng-1 and pAng-1 respectively), and P-selectin (sPsel and pPsel respectively) in patients with well controlled hypertension. Methods: A total of 35 aspirin-naive, hypertensive patients (29 male and six female; mean age 64 years) were compared with 30 (23 male, seven female, mean age 59 years) normotensive control subjects. Blood was collected for plasma VEGF, P-selectin, and Ang-1 (enzyme-linked immunoassay), intra-platelet levels of VEGF, Ang-1, and P-selectin, and platelet volume and mass. Research indices in hypertensive patients were studied before and after 3 months treatment with aspirin 75 mg daily. Results: Hypertensive patients had significantly higher plasma levels of VEGF (P = .04), Ang-1 (P < .001), as well as pVEGF (P = .008), pAng-1(P = .001), sPsel (P = .02), pPsel (P < .001), and mean platelet mass (P = .01) when compared with control subjects. After treatment with aspirin for 3 months, there were significant reductions in plasma VEGF (P = .01), pAng-1 (P = .04), sPsel (P = .001), and pPsel (P < .001) levels, but not levels of platelet VEGF and plasma Ang-1. Neither pVEGF nor pAng-1 correlated with blood pressure or with their respective plasma levels. Conclusions: The use of aspirin in high-risk hypertensive patients leads to a reduction in intra-platelet angiogenic growth factors and platelet activation. This may have implications for the use of aspirin in conditions (such as vascular disease) that have been associated with an increase in angiogenesis and platelet activation.

KW - angiopoeitin-1

KW - aspirin

KW - Hypertension

KW - P-selectin

KW - platelets

KW - vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=33846238204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846238204&partnerID=8YFLogxK

U2 - 10.1016/j.amjhyper.2006.03.001

DO - 10.1016/j.amjhyper.2006.03.001

M3 - Article

VL - 19

SP - 970

EP - 977

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 9

ER -